Form 4: Elicio Therapeutics Director Acquires Stock Options

Jay Venkatesan, a director of Elicio Therapeutics, acquired stock options for 7,900 shares of common stock on May 19, 2025.

Summary

• On May 19, 2025, Jay Venkatesan, a director of Elicio Therapeutics, acquired stock options to purchase 7,900 shares of the company's common stock.
• The exercise price of these options is $5.84 per share.
• The options vest fully on the earlier of May 19, 2026, or the next annual meeting of the company's stockholders after the grant date, contingent upon continued service to the issuer.
• The options expire on May 19, 2035.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing regarding stock option grants, indicating a neutral sentiment.

Industry Context

This is a standard Form 4 filing, reflecting a director's acquisition of stock options, a common form of executive compensation in the biotechnology industry. It provides transparency into insider transactions.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors and executives in biotech companies like Elicio Therapeutics.
• The vesting schedule of one year is fairly standard, aligning with industry norms for incentivizing long-term commitment.
• Comparable companies such as BioNTech or Moderna also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates

Keywords

stock options, director, Elicio Therapeutics, ELTX, Form 4, beneficial ownership, insider trading